Soleno Therapeutics to Participate in Upcoming November Investor Conferences
Event:
Date:
Time:
Event: Stifel 2024 Healthcare Conference
Date:
Time:
Event:
Date:
Time:
A live audio webcast and replay of the Guggenheim and Jefferies events will be available in the Investors section on the Company’s website at www.soleno.life.
About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company recently submitted an NDA to the FDA, supported by its Phase 3 development program, for its lead candidate, DCCR (diazoxide choline) extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS). For more information, please visit www.soleno.life.
Corporate Contact:
212-915-2578
Source: Soleno Therapeutics